Related Experiment Video
Updated: May 8, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
The interaction between prognostic and pharmacodynamic biomarkers.
L Bouranis1, M Sperrin, A Greystoke
1Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, UK.
British Journal of Cancer
|September 5, 2013
Summary
This study introduces a new framework for analyzing biomarker interactions. It demonstrates how certain biomarkers can have both prognostic and pharmacodynamic (PD) effects in cancer patients.
Area of Science:
- Biomarker discovery and validation
- Translational oncology research
- Statistical modeling in clinical trials
Background:
- Interactions between prognostic and pharmacodynamic (PD) biomarkers are understudied.
- Understanding these interactions is crucial for personalized cancer therapy.
- Cytokeratin 18 (CK18) is a potential biomarker in metastatic colorectal cancer.
Purpose of the Study:
- To develop and validate statistical models for assessing prognostic and PD biomarker interactions.
- To investigate the dual prognostic and PD characteristics of circulating cytokeratin 18 (CK18) in metastatic colorectal cancer patients.
- To provide a framework for analyzing longitudinal biomarker data.
Main Methods:
- Utilized linear mixed-effects models to analyze published longitudinal data.
- Assessed prognostic and PD utilities of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18.
- Data from 57 patients with metastatic colorectal cancer undergoing chemotherapy were analyzed.
Main Results:
- The statistical model successfully separated the prognostic/PD interaction from the pure prognostic effect for total CK18 (tCK18).
- This finding illustrates the principle of dual prognostic and PD characteristics for a single biomarker.
- The model for cleaved CK18 (ctCK18) did not show this separation.
Conclusions:
- Developed statistical models offer a framework for analyzing longitudinal data to detect prognostic/PD biomarker interactions.
- These models enhance the interpretation of biomarker data in clinical settings.
- The findings support the potential of CK18 as a biomarker with dual prognostic and PD roles.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...